FORMULATION AND DEVELOPMENT OF MUCOADHESIVE TABLETS OF LAMIVUDINE USING DIRECT COMPRESSION TECHNIQUE

The objective of the present work is to design mucoadhesive tablets of lamivudine for oral controlled release by direct compression using different binders. Lamivudine is anti viral drug used in the treatment of hepatitis B and HIV infections. It has a shorter half-life of 2-6 hrs, oral availability is 86% and it is eliminated rapidly from the plasma compartment within few hours. So, frequent administration is necessary to maintain its therapeutic concentration. In order to maintain the therapeutic concentrations of lamivudine modified release formulations are necessary. In the present work the mucoadhesive tablets of lamivudine was prepared to prolong the residence time at the site of application (or) absorption and to facilitate the intimate contact with the underlying absorption surface to improve and enhance the bioavailability. The mucoadhesive tablets of lamivudine were prepared by using Carbopol, Hydroxy propyl methylcellulose, xanthan gum.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24300843
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FORMULATION AND DEVELOPMENT OF MUCOADHESIVE TABLETS OF LAMIVUDINE USING DIRECT COMPRESSION TECHNIQUE

E. Gopinath, S. Monesh, K. Lousion, Sathyaraj. A.
1 links
Zenodo (CERN European Organization for Nuclear Research)
Advanced Drug Delivery Systems
article

FORMULATION AND DEVELOPMENT OF MUCOADHESIVE TABLETS OF LAMIVUDINE USING DIRECT COMPRESSION TECHNIQUE

E. Gopinath, S. Monesh, K. Lousion, Sathyaraj. A.
article en

Abstract

The objective of the present work is to design mucoadhesive tablets of lamivudine for oral controlled release by direct compression using different binders. Lamivudine is anti viral drug used in the treatment of hepatitis B and HIV infections. It has a shorter half-life of 2-6 hrs, oral availability is 86% and it is eliminated rapidly from the plasma compartment within few hours. So, frequent administration is necessary to maintain its therapeutic concentration. In order to maintain the therapeutic concentrations of lamivudine modified release formulations are necessary. In the present work the mucoadhesive tablets of lamivudine was prepared to prolong the residence time at the site of application (or) absorption and to facilitate the intimate contact with the underlying absorption surface to improve and enhance the bioavailability. The mucoadhesive tablets of lamivudine were prepared by using Carbopol, Hydroxy propyl methylcellulose, xanthan gum.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Advanced Drug Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon